Ahsan Habib MS, Darrell Sawmiller, Song Li, Sadia Afrin Munna, David Rongo, Shengnuo Fan, Jun Tian, Huayan Hou, Jin Zeng, Brian Giunta, Adam Smith, Takashi Mori, Glenn Currier, Douglas R Shytle, and Jun Tan
Alzheimer’s disease (AD) is characterized pathologically by the accumulation of neuritic plaques and neurofibrillary tangles in the brain and clinically by a progressive decline in cognitive function. Lithium is used primarily as a mood stabilizer for bipolar disorder and has been used for a long time to treat mania and depression. Furthermore, it has also been shown as preventing cognitive loss which indicated the therapeutic potential of this drug for AD. We hypothesized that an ionic co-crystal of lithium (LISPRO) prevent cognitive decline and associated pathology changes in cell culture and AD mouse models.
